These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32923165)

  • 1. Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response.
    Kotsafti A; Scarpa M; Cavallin F; Fassan M; Salmaso R; Porzionato A; Saadeh L; Cagol M; Alfieri R; Castoro C; Rugge M; Castagliuolo I; Scarpa M
    Oncoimmunology; 2020 Aug; 9(1):1804169. PubMed ID: 32923165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
    Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
    J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
    Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
    Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes.
    Xi M; Yang Y; Zhang L; Yang H; Merrell KW; Hallemeier CL; Shen RK; Haddock MG; Hofstetter WL; Maru DM; Ho L; Wu CC; Liu M; Lin SH
    Ann Surg; 2019 Apr; 269(4):663-670. PubMed ID: 29334555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
    Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
    Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
    Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
    Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.
    McLaren PJ; Barnes AP; Terrell WZ; Vaccaro GM; Wiedrick J; Hunter JG; Dolan JP
    Am J Surg; 2017 May; 213(5):915-920. PubMed ID: 28385379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?
    Voncken FE; Jiang H; Kim J; Guindi M; Brierley J; Knox J; Liu G; Horgan AM; Lister J; Darling G; Metser U; Wong RK
    Dis Esophagus; 2014 Aug; 27(6):552-9. PubMed ID: 23121504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
    Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
    Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms.
    Scarpa M; Kotsafti A; Fassan M; Scarpa M; Cavallin F; Nardi T; Pinto E; Alfieri R; Cagol M; Agostini M; Rugge M; Castagliuolo I; Castoro C
    Tumour Biol; 2017 Oct; 39(10):1010428317728683. PubMed ID: 29022493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing.
    Chiam K; Mayne GC; Watson DI; Woodman RJ; Bright TF; Michael MZ; Karapetis CS; Irvine T; Phillips WA; Hummel R; Wang T; Pimlott LK; Marri S; Astill DS; Ruszkiewicz AR; Thompson SK; Hussey DJ
    Ann Surg Oncol; 2018 Sep; 25(9):2731-2738. PubMed ID: 29987600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
    Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
    Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant chemoradiotherapy on perioperative immune function of patients with locally advanced esophageal cancer.
    Tan JT; Yang Y; Mao NQ; Liu DS; Huang DM; Pan H; Xie T; Pan Q; Yang L; Zhong JH; Zuo CT
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27766708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
    Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
    Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
    Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
    Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.